Table 2:

Predicted number of events in the DAPA-CKD population and sub-populations per 1000 patients over 10 years.

Subgroup	Event	Dapagliflozin	Placebo	Incremental
Overall population	HHF	39	58	–19
	Abrupt decline in kidney functiona	144	183	–39
	KRT	241	292	–51
	Dialysis	200	245	–45
	Transplant	41	47	–6
	ACM	288	371	–83
T2DM	HHF	61	91	–30
	Abrupt decline in kidney functiona	162	205	–43
	KRT	233	282	–49
	Dialysis	193	236	–43
	Transplant	40	46	–6
	ACM	321	408	–87
No T2DM	HHF	15	23	–8
	Abrupt decline in kidney functiona	112	144	–32
	KRT	253	312	–59
	Dialysis	210	262	–52
	Transplant	43	50	–7
	ACM	236	311	–75
eGFR <45 mL/min/1.73 m2	HHF	40	60	–20
	Abrupt decline in kidney functiona	159	204	–45
	KRT	253	309	–56
	Dialysis	210	259	–49
	Transplant	43	50	–7
	ACM	307	396	–89
eGFR ≥45 mL/min/1.73 m2	HHF	37	56	–19
	Abrupt decline in kidney functiona	124	157	–33
	KRT	224	269	–45
	Dialysis	185	225	–40
	Transplant	39	44	–5
	ACM	263	337	–74
Aged <65 years	HHF	23	34	–11
	Abrupt decline in kidney functiona	132	169	–37
	KRT	251	309	–58
	Dialysis	208	259	–51
	Transplant	43	50	–7
	ACM	234	309	–75
Aged ≥65 years	HHF	70	104	–34
	Abrupt decline in kidney functiona	156	196	–40
	KRT	222	267	–45
	Dialysis	184	223	–39
	Transplant	38	44	–6
	ACM	376	469	–94
Prior HF	HHF	257	375	–118
	Abrupt decline in kidney functiona	306	373	–67
	KRT	192	222	–30
	Dialysis	158	185	–27
	Transplant	34	37	–3
	ACM	520	622	–102
No prior HF	HHF	30	46	–15
	Abrupt decline in kidney functiona	130	166	–36
	KRT	245	298	–53
	Dialysis	203	250	–48
	Transplant	42	48	–7
	ACM	270	350	–80

^aDefined as a doubling of serum creatinine between two visits.